Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study.

Axel HegeleRainer HäußermannStefan SchultheisLennart SkrobekMeike VinkSebastian HollwegsMartin LudwigPetra HuweManfred MaywurmAnke Bartsch-PolleJost WeberMarkus ThiemerDenny Varughese

Published in: Journal of cancer research and clinical oncology (2024)

In real world more comorbid nmCRPC patients with a higher ECOG-PS and more aggressive tumors are treated with apalutamide plus ADT. Nevertheless efficacy results as well as side effects are similar in real-world compared to Spartan trial showing also a rapid, durable and deep PSA response with a median MFS of 43 months.

Keyphrases

prostate cancer
squamous cell carcinoma
small cell lung cancer
clinical trial
electronic health record
phase iii
big data
phase ii
deep learning
newly diagnosed